No registrations found.
ID
Source
Brief title
Health condition
Hypoxia; Hypoxic Pulmonary Vasoconstriction; Hypoxic Ventilatory Response.
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. Hypoxic Ventilatory Response (HVR);
2. Pulmonary Artery Pressure (PAP).
Secondary outcome
1. Systolic and diastolic cardiac functions;
2. Vital and ventilatory parameters;
3. Pain thresholds under hypoxia.
Background summary
Epo seems to have and effect on hypoxic sensing in the carotid body and might effect the sensing in the pulmonary vascular tree. We want to investigate if this is detectable and what an Epo analog like ARA290 does on the HVR and PAP.
Study objective
Are there effects of ARA290 and Epo on the ventilatory response to hypoxia. Are there effects of ARA290 and Epo on the gradient over the tricuspid valve during hypoxia a an estimation of the pulmonary artery pressure (PAPA). Does ARA290 and/or Epo affect the pain responses?
Study design
T = 0 min arrival in the laboratory;
T = 15 min: insertion of IV and arterial line and drawing of a blood sample for Hemoglobin
concentration measurement;
T = 30 min baseline measurements PAIN 10 min
ECHO 40 min RESPIRATION 40 min;
T = 120 min TREATMENT injection (ARA290, Epo, Placebo);
T = 150 min effect measurements PAIN 10 min
ECHO 40 min RESPIRATION 40 min;
T = 240 min End of Study.
Intervention
Healthy volunteers will each be seen for three sessions, with 2 weeks in between. Hypoxia will be induced using the computer driven Dynamic End-Tidal Forcing (DEF) Technique; end-tidal oxygen concentrations will be lowered to 5.8 kPa (about 45 mmHg) to reach an oxygen saturation of 80 ± 2 %, whereas the PCO2 level remains constant (end-tidal concentration is rest endtidal PCO2 + 2-3 mmHg). The subjects will breathe in and out through a face mask with a pneumotachograph to measure ventilation on a breath-to-breath basis. The maximum pressure difference across the tricuspid valve (∆P max) will be measured using Doppler echocardiography. An arterial line will provide information about the arterial blood gas and BP. Each time one substance, either NaCl 0,9%, Erythropoietin or ARA290, will be administered by intravenous injection. Cardiac output will be measured with the Vigileo monitor (Edwards Lifesciences) and by cross sectional echocardiography, using the diameter of the left ventricular outflow tract, with the image frozen in midsystole, to calculate the cross sectional area, assuming a circular profile. We will measure aortic blood velocity by continuous wave Doppler.
R.R. Berendsen
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301
r.r.berendsen@lumc.nl
R.R. Berendsen
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301
r.r.berendsen@lumc.nl
Inclusion criteria
The major inclusion criteria is that the subject has echo evidence of tricuspid regurgitation during systole, which is not clinically relevant but in fact can be demonstrated in most normal individuals.
Exclusion criteria
1. Obesity (BMI > 35);
2. Presence of medical disease (heart-, lung-, liver-, kidney-, neurologic disease; diabetes m.; pyrosis; diaphragmatic hernia);
3. Presence of psychiatric disease;
4. History of chronic alcohol or illicit drug use;
5. Allergy to study medications. For females we require the use of oral contraceptives.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL2983 |
NTR-old | NTR3131 |
Other | METC LUMC / CCMO : p10144 / NL32314.058.10; |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |